All Stories

  1. Novel targeted strategies to overcome resistance in small-cell lung cancer: focus on PARP inhibitors and rovalpituzumab tesirine

    Article • Expert Review of Anticancer Therapy, May 2019, Taylor & Francis

    Professor Godefridus J Peters, Robin van den Borg